450 related articles for article (PubMed ID: 19283656)
21. Delayed acquisition of neonatal reflexes in newborn primates receiving a thimerosal-containing hepatitis B vaccine: influence of gestational age and birth weight.
Hewitson L; Houser LA; Stott C; Sackett G; Tomko JL; Atwood D; Blue L; White ER
J Toxicol Environ Health A; 2010; 73(19):1298-313. PubMed ID: 20711932
[TBL] [Abstract][Full Text] [Related]
22. Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage.
Luman ET; Fiore AE; Strine TW; Barker LE
JAMA; 2004 May; 291(19):2351-8. PubMed ID: 15150207
[TBL] [Abstract][Full Text] [Related]
23. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years.
Thompson WW; Price C; Goodson B; Shay DK; Benson P; Hinrichsen VL; Lewis E; Eriksen E; Ray P; Marcy SM; Dunn J; Jackson LA; Lieu TA; Black S; Stewart G; Weintraub ES; Davis RL; DeStefano F;
N Engl J Med; 2007 Sep; 357(13):1281-92. PubMed ID: 17898097
[TBL] [Abstract][Full Text] [Related]
24. Impact of the Joint Statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices.
Hurie MB; Saari TN; Davis JP
Pediatrics; 2001 Apr; 107(4):755-8. PubMed ID: 11335754
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the Joint Statement on Thimerosal in Vaccines.
Thomas AR; Fiore AE; Corwith HL; Cieslak PR; Margolis HS
Pediatr Infect Dis J; 2004 Apr; 23(4):313-8. PubMed ID: 15071284
[TBL] [Abstract][Full Text] [Related]
26. A Cross-Sectional Study of the Association between Infant Hepatitis B Vaccine Exposure in Boys and the Risk of Adverse Effects as Measured by Receipt of Special Education Services.
Geier DA; Kern JK; Homme KG; Geier MR
Int J Environ Res Public Health; 2018 Jan; 15(1):. PubMed ID: 29329213
[TBL] [Abstract][Full Text] [Related]
27. Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines.
Dórea JG
Neurochem Res; 2017 Oct; 42(10):2673-2685. PubMed ID: 28439753
[TBL] [Abstract][Full Text] [Related]
28. Hair mercury in breast-fed infants exposed to thimerosal-preserved vaccines.
Marques RC; Dórea JG; Fonseca MF; Bastos WR; Malm O
Eur J Pediatr; 2007 Sep; 166(9):935-41. PubMed ID: 17237965
[TBL] [Abstract][Full Text] [Related]
29. When science is not enough - a risk/benefit profile of thiomersal-containing vaccines.
Clements CJ; McIntyre PB
Expert Opin Drug Saf; 2006 Jan; 5(1):17-29. PubMed ID: 16370953
[TBL] [Abstract][Full Text] [Related]
30. Neurotoxic character of thimerosal and the allometric extrapolation of adult clearance half-time to infants.
Magos L
J Appl Toxicol; 2003; 23(4):263-9. PubMed ID: 12884410
[TBL] [Abstract][Full Text] [Related]
31. Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults.
Rebedea I; Diaconescu IG; Bach D; Bartelsen O; Arndtz N
Vaccine; 2006 Jun; 24(25):5320-6. PubMed ID: 16707195
[TBL] [Abstract][Full Text] [Related]
32. A dose-response relationship between organic mercury exposure from thimerosal-containing vaccines and neurodevelopmental disorders.
Geier DA; Hooker BS; Kern JK; King PG; Sykes LK; Geier MR
Int J Environ Res Public Health; 2014 Sep; 11(9):9156-70. PubMed ID: 25198681
[TBL] [Abstract][Full Text] [Related]
33. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism.
Geier DA; Geier MR
Med Sci Monit; 2004 Mar; 10(3):PI33-9. PubMed ID: 14976450
[TBL] [Abstract][Full Text] [Related]
34. Low-dose Thimerosal in pediatric vaccines: Adverse effects in perspective.
Dórea JG
Environ Res; 2017 Jan; 152():280-293. PubMed ID: 27816865
[TBL] [Abstract][Full Text] [Related]
35. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
36. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine.
Barregard L; Rekić D; Horvat M; Elmberg L; Lundh T; Zachrisson O
Toxicol Sci; 2011 Apr; 120(2):499-506. PubMed ID: 21252391
[TBL] [Abstract][Full Text] [Related]
37. Modeling neurodevelopment outcomes and ethylmercury exposure from thimerosal-containing vaccines.
Dórea JG; Marques RC
Toxicol Sci; 2008 Jun; 103(2):414-5; author reply 416. PubMed ID: 18364366
[No Abstract] [Full Text] [Related]
38. Update: expanded availability of thimerosal preservative-free hepatitis B vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jul; 49(28):642, 651. PubMed ID: 10926308
[TBL] [Abstract][Full Text] [Related]
39. Infants' exposure to aluminum from vaccines and breast milk during the first 6 months.
Dórea JG; Marques RC
J Expo Sci Environ Epidemiol; 2010 Nov; 20(7):598-601. PubMed ID: 20010978
[TBL] [Abstract][Full Text] [Related]
40. Early exposure to thimerosal-containing vaccines and children's cognitive development. A 9-year prospective birth cohort study in Poland.
Mrozek-Budzyn D; Majewska R; Kiełtyka A
Eur J Pediatr; 2015 Mar; 174(3):383-91. PubMed ID: 25185528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
